Tags

Type your tag names separated by a space and hit enter

Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme® a medical device mouth spray against the common cold.
J Med Virol. 2021 03; 93(3):1792-1795.JM

Abstract

BACKGROUND

The coronavirus disease 2019 (COVID-19) pandemic calls for effective and safe treatments. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 actively replicates in the throat, unlike SARS-CoV, and shows high pharyngeal viral shedding even in patients with mild symptoms of the disease. HCoV-229E is one of four coronaviruses causing the common cold. In this study, the efficacy of ColdZyme® (CZ-MD), a medical device mouth spray, was tested against SARS-CoV-2 and HCoV-229E in vitro. The CZ-MD provides a protective glycerol barrier containing cod trypsin as an ancillary component. Combined, these ingredients can inactivate common cold viruses in the throat and mouth. The CZ-MD is believed to act on the viral surface proteins that would perturb their entry pathway into cells. The efficacy and safety of the CZ-MD have been demonstrated in clinical trials on the common cold.

METHOD OF STUDY

The ability of the CZ-MD to inactivate SARS-CoV-2 and HCoV-229E was tested using an in vitro virucidal suspension test (ASTM E1052).

RESULTS

CZ-MD inactivated SARS-CoV-2 by 98.3% and HCoV-229E by 99.9%.

CONCLUSION

CZ-MD mouth spray can inactivate the respiratory coronaviruses SARS-CoV-2 and HCoV-229E in vitro. Although the in vitro results presented cannot be directly translated into clinical efficacy, the study indicates that CZ-MD might offer a protective barrier against SARS-CoV-2 and a decreased risk of COVID-19 transmission.

Authors+Show Affiliations

Faculty of Food Science and Nutrition, School of Health Sciences, University of Iceland, Reykjavík, Iceland. Zymetech, Reykjavík, Iceland.Zymetech, Reykjavík, Iceland.Enzymatica AB, Lund, Sweden. Medical Faculty, Lund University, Lund, Sweden.Zymetech, Reykjavík, Iceland.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32975843

Citation

Gudmundsdottir, Ágústa, et al. "Inactivation of SARS-CoV-2 and HCoV-229E in Vitro By ColdZyme® a Medical Device Mouth Spray Against the Common Cold." Journal of Medical Virology, vol. 93, no. 3, 2021, pp. 1792-1795.
Gudmundsdottir Á, Scheving R, Lindberg F, et al. Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme® a medical device mouth spray against the common cold. J Med Virol. 2021;93(3):1792-1795.
Gudmundsdottir, Á., Scheving, R., Lindberg, F., & Stefansson, B. (2021). Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme® a medical device mouth spray against the common cold. Journal of Medical Virology, 93(3), 1792-1795. https://doi.org/10.1002/jmv.26554
Gudmundsdottir Á, et al. Inactivation of SARS-CoV-2 and HCoV-229E in Vitro By ColdZyme® a Medical Device Mouth Spray Against the Common Cold. J Med Virol. 2021;93(3):1792-1795. PubMed PMID: 32975843.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme® a medical device mouth spray against the common cold. AU - Gudmundsdottir,Ágústa, AU - Scheving,Reynir, AU - Lindberg,Fredrik, AU - Stefansson,Bjarki, Y1 - 2020/10/14/ PY - 2020/09/01/received PY - 2020/09/21/revised PY - 2020/09/23/accepted PY - 2020/9/26/pubmed PY - 2021/3/11/medline PY - 2020/9/25/entrez KW - cell cultures KW - coronavirus KW - microbial cultures KW - respiratory tract SP - 1792 EP - 1795 JF - Journal of medical virology JO - J Med Virol VL - 93 IS - 3 N2 - BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic calls for effective and safe treatments. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 actively replicates in the throat, unlike SARS-CoV, and shows high pharyngeal viral shedding even in patients with mild symptoms of the disease. HCoV-229E is one of four coronaviruses causing the common cold. In this study, the efficacy of ColdZyme® (CZ-MD), a medical device mouth spray, was tested against SARS-CoV-2 and HCoV-229E in vitro. The CZ-MD provides a protective glycerol barrier containing cod trypsin as an ancillary component. Combined, these ingredients can inactivate common cold viruses in the throat and mouth. The CZ-MD is believed to act on the viral surface proteins that would perturb their entry pathway into cells. The efficacy and safety of the CZ-MD have been demonstrated in clinical trials on the common cold. METHOD OF STUDY: The ability of the CZ-MD to inactivate SARS-CoV-2 and HCoV-229E was tested using an in vitro virucidal suspension test (ASTM E1052). RESULTS: CZ-MD inactivated SARS-CoV-2 by 98.3% and HCoV-229E by 99.9%. CONCLUSION: CZ-MD mouth spray can inactivate the respiratory coronaviruses SARS-CoV-2 and HCoV-229E in vitro. Although the in vitro results presented cannot be directly translated into clinical efficacy, the study indicates that CZ-MD might offer a protective barrier against SARS-CoV-2 and a decreased risk of COVID-19 transmission. SN - 1096-9071 UR - https://www.unboundmedicine.com/medline/citation/32975843/Inactivation_of_SARS_CoV_2_and_HCoV_229E_in_vitro_by_ColdZyme®_a_medical_device_mouth_spray_against_the_common_cold_ L2 - https://doi.org/10.1002/jmv.26554 DB - PRIME DP - Unbound Medicine ER -